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Editorial
Leclercia adecarboxylata was initially described by Leclerc in 
1962 as Escherichia adecarboxylata, a member of the pigmented 
Enterobacteriaceae group (Enteric group 41) [1]. However, based on 
the detailed phenotypic and genotypic characterization of the species 
(Tamura et al.), it was renamed in 1986 to L. adecarboxylata [2]. L. 
adecarboxylata is a typical member of the Enterobacterales order: it 
is a Gram-negative, lactose-positive, motile rod [3]. This species in 
abundantly found in nature (e.g., aquatic environments, drinking 
water, soil and on the surface of various objects). L. adecarboxylata 
was previously considered an uncommon isolate from human clinical 
samples and scarce clinical data was available about its relevance in 
infectious processes. However, the significance of this species in 
clinical cases has recently been re-evaluated. This pathogen has 
been reported as a causative agent in bacteremia/sepsis, diarrhea, 
pneumonia, peritonitis, septic arthritis, skin and soft tissue infections, 
abscesses and urinary tract infections, both in immunocompromised 
(e.g., leukemia or other malignancy, AIDS) and immunocompetent 
individuals [4]. Microbiological laboratories, whose methods only 
include classical biochemical methods, may be inadequate in the 
correct identification of L. adecarboxylata, because this species shares 
many biochemical characteristics with its sibling species in the order 
Enterobacterales. This is especially true in conjuction with Escherichia 
coli, as L. adecarboxylata is phenotypically and biochemially very 
similar to this common gut bacteria [5]. 
Biochemical reaction-based identification systems (e.g., VITEK) 
and selective Chromogenic Media (e.g., CHROM ID® CPS® Elite 
Agar or CPSE) may offer a cost-effective solution to the correct 
identification of this species [4]. Biochemical reactions that may be 
useful in the differentiation of E. coli from L. adecarboxylata include 
lysine decarboxylase, malonate assimilation and acid production 
from arabitol and cellobiose, however, these are only reliable in the 
case of wild-type strains [5]. With the advent of rapid molecular 
methods (polymerase chain reaction) and typing techniques, 
Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass 
Spectrometry (MALDI-TOF MS) and Next Generation Sequencing 
(NGS) in clinical microbiology laboratories, the perceived incidence 
and significance of this pathogen has increased substantially, and it 
can no longer be rejected as ‘just another contaminant’ [4]. 
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L. adecarboxylata strains are naturally sensitive to various 
antibiotics, such as penicillinase-stable penicillins and other 
beta-lactams, sulfamethoxazole/trimethoprim, tetracyclines, 
aminoglycosides, fluoroquinolones, chloramphenicol, azithromycin 
and nitrofurantoin [4]. In contrast, they have intrinsic resistance to 
penicillin G, oxacillin, glycopeptides, non-azithromycin macrolides 
(erythromycin, roxithromycin, clarithromycin, ketolides), 
clindamycin, streptogramins, linezolid, rifampicin, fusidinic acid and 
fosfomycin [4,5]. Some reports suggest that resistance to fosfomycin 
may be an additional differentiating factor between E. coli and L. 
adecarboxylata, however, due to the increase in fosfomycin resistance 
in E. coli, this may also lead to discrepant results. This species is also 
affected by the rapid emergence of drug resistance in Gram-negative 
pathogens, a case of a multidrug-resistant L. adecarboxylata isolate 
has already been described [6,7]. 
The clinical relevance of isolated L. adecarboxylata from various 
specimens in the microbiology laboratory need to be evaluated based 
on the clinical picture. For this reason, continuous communication 
between the clinicians and the diagnostic lab is crucial. Physicians 
(ranging from general practitioners to infectious disease specialists) 
should familiarize themselves with “old/new” pathogens, that may 
cause disease for the adequate diagnosis and therapy of their patients 
[8].
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